ClinicalTrials.gg
RecruitingNCT04471987DODEKAUpdated Sep 10, 2026

Safety and Early Signs of Efficacy of IL12-L19L19.

A Phase 1 interventional study of IL12-L19L19 and IL12-L19L19 in Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Philogen S.p.A.. Recruiting at 11 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Philogen S.p.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 323 studies in Neoplasm Metastasis with a site in Germany — 52 open to participants now, 91 under way, 36 of them phase 3. Neoplasm Metastasis · Germany.

Planned enrollment
217th of 292
80 · median 214
Started
2020
with 17 others
Phase 1
37 of 323
4 open now
Primary completion
2026-12
later than 28 of 90 live
Registered
233rd of 323
by date

Among the 323 studies in Neoplasm Metastasis with a site in Germany, this one is the 217th largest by planned enrollment of the 292 interventional ones that give a count, is one of 18 that started in 2020, is one of 37 in phase 1, reaches primary completion later than 28 of the 90 other live ones, and was the 233rd registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

52 of the 323 studies in Neoplasm Metastasis with a site in Germany are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 691 Neoplasm Metastasis studies recruiting now, 538 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 323 studies in Neoplasm Metastasis with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy.

The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD).

The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.

03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female aged 18 to 80 years at the time of consent.
  2. Patients must have a histological or cytological diagnosis of advanced/ immunotherapy responsive solid carcinoma for which immune checkpoint blockade is approved, that has progressed on immune checkpoint-blockade therapy.
  3. Patients must have received an immune checkpoint blockade therapy-based regimen as prior treatment.
  4. Only patients without other therapeutic alternatives with curative or survival prolonging potential per investigator judgement are able to participate.
  5. Subjects must have had clinical benefit in terms of disease control (CR/PR/SD) while on treatment defined as ≥ 3 month free from progression from initial imaging documenting advanced/metastatic disease followed by radiographic disease progression after checkpoint inhibitor per investigator's opinion.
  6. Patients must have progressive disease or relapse at the time of screening.
  7. Patients may have previously received chemotherapy, immunotherapy or radiation therapy. Such therapies must be completed at least 4 weeks prior to study drug administration. Radiotherapy within 4 weeks of the first dose of study drug, is allowed for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass. During the expansion part, to allow evaluation of response to treatment, patients must have remaining that has not been irradiated.
  8. (ECOG) performance status ≤ 2.
  9. Patient has an estimated of at least 12 weeks.
  10. At least one unidimensionally measurable lesion either by computed tomography (CT), MRI or PET/CT as defined by (v. 1.1) for solid tumors.
  11. Documented negative test for --. For HBV serology: the determination of HBsAg, and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  12. All acute toxic effects (excluding alopecia and fatigue) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) (CTCAE) (v. 5.0) Grade ≤ 1.
  13. Full resolution of checkpoint blockade therapy-related adverse effects (including immune-related adverse effects) and no treatment for these AEs for at least 4 weeks prior to the time of enrollment. The only exception are patients with checkpoint blockade induced hypothyroidism and hypophysitis if these patients are on stable maintenance therapy with on levothyroxine or (≤ 10 mg prednisone equivalent) for at least 2 months prior dosing.
  14. No history of severe immune related adverse effects from prior given immune checkpoint blockade therapy (CTCAE Grade 4; CTCAE Grade 3 requiring treatment >4 weeks).
  15. Female patients: negative blood pregnancy test at Screening for women of (WOCBP)*. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.
  16. Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.
  17. Negative TB test (e.g. Mantoux or Quantiferon assay).
  18. A personally signed and dated document indicating that the subject has been informed of all pertinent aspects of the study and has given consent to participate in the study.
  19. Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

    • Women of childbearing potential are defined as females who have experienced menarche, are not (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)

Exclusion criteria

Exclusion Criteria:

  1. Subjects who participated in an drug or device study within 4 weeks prior to study treatment start.
  2. Radiotherapy within 4 weeks prior to study treatment start.
  3. Active or history of disease that might deteriorate when receiving an immuno-stimulatory agent.
  4. Patients with primary brain tumors or CNS disease (including ).
  5. Patient taking herbal medications within 7 days prior to study treatment start.
  6. Known history of allergy to an in study medication or any other intravenously administered human proteins/peptides/antibodies.
  7. (ANC) \< 1.5 x 10\^9/L, \< 100 x 10\^9/L or (Hb) \< 9.0 g/dl.
  8. Chronically impaired renal function as indicated by \< 60 mL/min or serum creatinine > 1.5 .
  9. Inadequate liver function (, AST, ALP ≥ 2.5 x ULN or total ≥ 2.0 x ULN). At the discretion of the investigator, an increased exclusion threshold for patients with liver can be accepted as follows: ALT, AST, ALP and bilirubin ≥ 5 x ULN.
  10. Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
  11. History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
  12. Heart insufficiency (> Grade II, (NYHA) criteria).
  13. cardiac arrhythmias or requiring permanent medication.
  14. Abnormal or any other abnormalities observed during baseline and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current, or a history of /QTc prolongation would be excluded. In particular:

    • patients with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of QTc >480 milliseconds using Fredricia's QT correction formula) are excluded;
    • patients with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of prolonged QT syndrome) are excluded;
    • patients who require the use of concomitant medications that prolong the QT/QTc interval are excluded.
  15. Uncontrolled hypertension as defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg at 3 consecutive measurements performed within one week. Note: if the first blood pressure measurement is below threshold for systolic or diastolic blood pressure, it is not required to repeat the measurement.
  16. Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
  17. Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
  18. Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of study treatment start.
  19. Pregnancy or breast-feeding.
  20. Systemic chronic therapy (>10 mg/day prednisone or equivalent) or any other therapy within 14 days prior to study treatment start. Topical, inhaled, nasal and ophthalmic steroids are allowed.
  21. Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
  22. Concurrent or previous (other than the indication for this trial), unless a complete remission without further recurrence was achieved at least 2 years prior to study treatment start.
  23. Growth factors or immunomodulatory agents within 7 days prior to study treatment start.
  24. Serious, non-healing wound, ulcer or bone fracture.
  25. Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
  26. Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
  27. Any recent within 4 weeks prior to treatment or plan to receive vaccination during the study.
Terms in these criteria, in plain language(34)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Treatment

    The study will take place in two stages: 1. In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached. 2. Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level.

    Drug: IL12-L19L19

Interventions

  • DrugIL12-L19L19

    Part I - The dose escalation is designed with an initial accelerated phase followed by a standard 3+3 design. Cohorts contain one patient until first instance of moderate toxicity or a DLT in the DLT observation period (28 days). With the second occurrence of moderate toxicity or occurrence of a DLT the accelerated phase will be terminated and the dose escalation will continue with a 3+3 dose escalation. Initiation of the study treatment for an individual subject will occur not less than 7 days after initiation of the study treatment for the previous patient. Not more than 2 patients are to be treated simultaneously within their DLT observation period (i.e., Day 1 to Day 28). Part II - Dose expansion: Once the dose escalation is completed, additional 20 patients will be enrolled at the RD to better understand the safety profile and to explore early signs of efficacy in different disease indications.

    Also known as: Dodekin

  • DrugIL12-L19L19

    Patients initially receive 8 consecutive administrations of IL12-L19L19 every week. At the end of this eight weeks treatment window, a tumor assessment is performed and those patients who achieve a clinical benefit (SD, PR, CR) may continue treatment with IL12-L19L19 as a biweekly maintenance therapy until disease progression, unacceptable toxicity, withdrawal of consent, at the discretion of the investigator or up to 1 year from study treatment start.

    Also known as: Dodekin

06

What researchers measure

Primary outcomes

  1. For Part I: DLT

    Occurrence of dose limiting toxicity (DLT) in dose escalation part of the study.

    Time frame: From Day 1 to Day 28 of the treatment

  2. For Part I: MAD

    Definition of Maximum Administered Dose (MAD) (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level)

    Time frame: From Day 1 to Day 28 of the treatment

  3. For Part I: MTD and RD

    Defining the Maximum Tolerated Dose (MTD) and recommendation of the Recommended Dose (RD): when the DLT rate reaches 33% in a cohort, the next lower dose level will be called the MTD (so long as the DLT rate is less than 33%). Accordingly, the recommended dose (RD) for the Dose Expansion cohort will be the MTD.

    Time frame: From Day 1 to Day 28 of the treatment

  4. Safety (AE)

    Safety of administration of IL12-L19L19, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient

  5. Safety (SAE)

    Safety of administration of IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient

  6. Safety (DILI)

    Evaluation of possible Drug Induce Liver Injury, caused by IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)

    Time frame: Throughout study completion for each patient, a maximum of 24 weeks for each patient

Secondary outcomes

  1. Plasma concentration of IL12-L19L19

    Evaluation of individual plasma concentration of IL12-L19L19

    Time frame: 30 min prior injection in week from 1 to 8, at End-of-Treatment Visit and Follow Up 1; in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2h, 4h and 24h after end of infusion

  2. AUC of IL12-L19L19

    Estimation of AUC of IL12-L19L19, as data permit

    Time frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion

  3. Tmax of IL12-L19L19

    Estimation of Tmax of IL12-L19L19, as data permit

    Time frame: In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion

  4. T1/2 of IL12-L19L19

    Estimation of T1/2 of IL12-L19L19, as data permit

    Time frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion

  5. Cmax of IL12-L19L19

    Estimation of Cmax of IL12-L19L19, as data permit

    Time frame: in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion

  6. HAFA

    Formation of human anti-fusion protein antibodies (HAFA) against IL12-L19L19

    Time frame: At week 1, 2, 3 and 4

  7. For Part II: ORR

    Objective Response Rate (ORR, consisting of complete response (CR) + partial response (PR)), is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period. Response duration usually is measured from the time of initial response until documented tumor progression. ORR is the sum of partial responses (PR) plus complete responses (CR), based on Response Evaluation Criteria in Solid Tumors (RECIST) (v. 1.1) criteria.

    Time frame: At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.

  8. For Part II: DoR

    The duration of overall response is measured from the time measurement criteria are first met for CR/PR (whichever is first recorded) untile the first date that recurrent or PD is objectively documented.

    Time frame: At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.

  9. For Part II: PFS

    Progression Free Survival (PFS) the time from enrolment to progression or death from any cause.

    Time frame: At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.

  10. For Part II: OS

    Overall Survival (OS) is defined beginning from enrolment to death from any cause

    Time frame: At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.

07

Study locations

9 of 11 sites recruiting
  • Universitaetsklinik Hamburg-Eppendorf
    Hamburg, Free and Hanseatic City of Hamburg, Germany
    Recruiting
    • Franziska Westendorf, Prof. · Contact
    • Franziska Westendorf, Prof. · Principal investigator
  • Universitätsklinikum Heidelberg, Nationalen Centrum für Tumorerkrankungen (NCT), Dermatoonkologie
    Heidelberg, Heidelberg 69120, Germany
    Recruiting
    • Ines Bertlich, Dr. · Contact
    • Ines Bertlich, Dr. · Principal investigator
  • Universitätsklinikum Leipzig, Klinik für Dermatologie, Venerologie und Allergologie
    Leipzig, Leipzig 04103, Germany
    Recruiting
    • Jan Christoph Simon, Dr. med. · Contact
    • Jan Christoph Simon, Dr. med. · Principal investigator
  • Universitätsklinikum Tübingen, Klinik für Innere Medizin VIII Medizinische Onkologie und Pneumologie
    Tübingen, 72076, Germany
    Recruiting
    • Ulrich Lauer, Dr. med. · Contact
    • Ulrich Lauer, Dr. med. · Principal investigator
  • IEO - Istituto Europeo di Oncologia
    Milan, Italy, Italy
    Recruiting
    • Giuseppe Curigliano, Prof. MD · Contact
    • Giuseppe Curigliano, Prof. MD · Principal investigator
  • Fondazione IRCCS Istituto Nazionale dei Tumori
    Milan, 20133, Italy
    Active, not recruiting

    Not enrolling at this site.

  • Azienda Ospedaliero-Universitaria San Luigi Gonzaga
    Orbassano, Italy
    Not yet recruiting
    • Silvia Novello · Contact
    • Silvia Novello · Principal investigator
  • Universitätsspital Basel
    Basel, Basel CH-4031, Switzerland
    Recruiting
    • Heinz Läubli · Contact
    • Heinz Läubli · Principal investigator
  • Insel Gruppe AG
    Bern, Canton of Bern 3010, Switzerland
    Recruiting
    • Sabine Schmid, Dr. med. · Contact
    • Sabine Schmid, Dr. med. · Principal investigator
  • Geneva University Hospital, Oncology Department
    Geneva, Canton of Geneva 1211, Switzerland
    Recruiting
    • Nicolas Mach, Prof. MD · Contact
    • Nicolas Mach, Prof. MD · Principal investigator
  • Oncology Institute of Southern Switzerland
    Bellinzona, 6500, Switzerland
    Recruiting
    • Martina Imbimbo, Dr. Med · Contact
    • Martina Imbimbo, Dr. Med · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2026, 77 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 77 months is above that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2020
First posted
Jul 15, 2020
StartActual
Jul 1, 2020
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04471987
Lead sponsor
Philogen S.p.A.
Responsible party
Sponsor
First posted
Jul 15, 2020
Start date
Jul 1, 2020
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Sep 10, 2026

Study contacts

Jacqueline Mock, PhD
Contact
regulatory@philogen.com
+41 435448804
Federica Bastioli, Pharmaceutical Chemist
Contact
regulatory@philogen.com
+39 057717816

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion